Abstract
We have recently reported that a defective dopamine D1-receptor function leading to the failure of dopamine to inhibit Na,K-ATPase and Na,H-exchanger in proximal tubules may cause sodium retention and contribute to hypertension observed in obese Zucker rats (Hypertension 34:1091-1096, 1999). The present study was designed to test the hypothesis that the defect in D1-receptor function is a result of hyperinsulinemia seen in obese Zucker rats. We designed experiments to study D1-receptor function in obese Zucker rats treated with rosiglitazone as it lowers plasma insulin by improving insulin sensitivity. A group of untreated lean and obese Zucker rats served as control. We found that rosiglitazone treatment (10 mg/kg, p.o. for 4 weeks) caused significant decreases in plasma insulin, blood glucose and blood pressure while increasing 24 hour renal sodium excretion in obese-treated in comparison with obese-untreated Zucker rats. In the isolated renal proximal tubules obtained from untreated lean Zucker rats, dopamine caused concentration-dependent inhibition of Na,K-ATPase and Na,H-exchanger activities but this inhibitory effect was almost blunted in untreated obese Zucker rats. Interestingly, in rosiglitazone-treated obese Zucker rats, the inhibitory effect of dopamine on Na,K-ATPase and Na,H-exchanger activities was similar to that observed in lean Zucker rats. This was accompanied by a similar restoration in renal D1-receptor numbers in treated obese Zucker rats. We propose that there exists an interaction between increased plasma insulin and renal D1-receptors in obese Zucker rats. The restoration of renal D1-receptor function by lowering plasma insulin levels with rosiglitazone may have contributed to the increase in sodium excretion and lowering of blood pressure in obese Zucker rats.